Anti-CDK16 TripleA Polyclonal antibody in breast cancer research

May 2022 (Department of Thyroid and Breast Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China)

Breast cancer is the most common malignancy and the leading cause of cancer-associated death in women.

This study (Li, X. et al., 2022) reports new evidence showing that cyclin-dependent kinase 16 (CDK16) plays a critical role in triple-negative breast cancer and its potential role as a therapeutic target for breast cancer.

Anti-CDK16 TripleA Polyclonal antibody in breast cancer research

Here are the significant findings of the study:

👉 CDK16 is highly expressed in breast cancer, particularly in triple-negative breast cancer.
👉 The elevated CDK16 expression is correlated with poor outcomes in breast cancer patients.
👉 CDK16 can improve cancer cells' proliferation and migration ability in vitro and promote tumor growth and metastasis in vivo.
👉 Both genetic knockdown and pharmacological inhibition of CDK16 significantly suppress the tumor progression.

The image shows the immunochemical staining of breast cancer tissue from a female, age 50 (source: the Human Protein Atlas).

The immunohistochemistry on breast cancer tissue was performed using our Anti-CDK16 TripleA Polyclonal antibody (HPA001366).

Whole artical read here: